样本量计算:成组设计的病例对照研究

2017-09-01 佚名 医咖会微信号

样本量的计算直接影响着临床试验的阴性或者阳性,而如何计算样本量实现效益与经济的平衡,是非常关键的问题。本公众号将持续转载报道医咖会整理的样本量计算系列推文,以便掌握样本量计算方法,助力临床试验设计

样本量的计算直接影响着临床试验的阴性或者阳性,而如何计算样本量实现效益与经济的平衡,是非常关键的问题。本公众号将持续转载报道医咖会整理的样本量计算系列推文,以便掌握样本量计算方法,助力临床试验设计

1、问题与数据

某研究者拟进行一项病例对照研究,探讨吸烟与肺癌的关系。选择肺癌患者为病例组,选择非肺癌患者为对照组。预期比值比OR=2.0,对照组人群中的吸烟率约为20%,设α=0.05,β=0.10。拟定病例组和对照组采用相等样本量,请问如何估计病例组和对照组的样本量?

2、对问题的分析

研究者的设计为病例对照研究,并且病例组和对照组各为一组,因此该设计类型为成组设计的病例对照研究。病例对照研究中,我们把想要探讨的危险因素称为暴露。

如果我们关注的暴露因素有多个,则计算样本量的原则一般如下:1)以最想关注的那个暴露因素计算得到的样本量为准;2)计算所有的暴露因素应有的样本量,然后取最大值。

3、PASS软件计算样本量方法

1)选择Proportions→Two Independent Proportions→Test (Inequality)→Test for Two Proportions[Odds Ratios]

2)Find (Solve for)中选择N1,Power (1-Beta)中选择0.9,Alpha (Significance Level)中选择0.05,N2 (Sample Size Group 2)中选择Use R,R (Sample Allocation Ratio)中选择1.0,OR1 (Odds Ratio|H1=O1/O2)中填入2.0,P2 (Control Group Proportion)中选择0.2。其它选择为默认选项后,点击RUN。

4、结果解读

PASS软件给出了样本量计算的结果、参考文献、报告中的名词定义和总结性描述。在样本量计算结果中我们需要关注以下两列:

1)Sample Size Grp 1 (N1):病例组样本量。本研究的病例组需要230例研究对象。

2)Sample Size Grp 2 (N2):对照组样本量。本研究的对照组需要230例研究对象。

5、撰写结论

本研究为成组设计的病例对照研究。病例组为肺癌患者,对照组为非肺癌患者,吸烟为主要观察的暴露因素。根据既往文献报道,对照组(非肺癌患者)人群中的吸烟率约为20%。预期OR=2.0,设α=0.05,β=0.10。利用PASS 11软件计算得到病例组和对照组的样本量N1=N2=230例。假定研究对象的无应答率为10%,则需样本量N1=N2=230÷0.9=256例。假定问卷合格率为90%,则共需样本量为N1=N2=256÷0.9=284例。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1984130, encodeId=024319841307e, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Dec 24 04:54:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756160, encodeId=d9d31e561605c, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Mon Apr 30 22:54:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669374, encodeId=3dca16693e499, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Jan 22 01:54:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775338, encodeId=0fce1e75338cd, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Oct 24 12:54:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283474, encodeId=737f12834e408, content=<a href='/topic/show?id=302e6204212' target=_blank style='color:#2F92EE;'>#样本量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62042, encryptionId=302e6204212, topicName=样本量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sun Sep 03 11:54:00 CST 2017, time=2017-09-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1984130, encodeId=024319841307e, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Dec 24 04:54:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756160, encodeId=d9d31e561605c, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Mon Apr 30 22:54:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669374, encodeId=3dca16693e499, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Jan 22 01:54:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775338, encodeId=0fce1e75338cd, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Oct 24 12:54:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283474, encodeId=737f12834e408, content=<a href='/topic/show?id=302e6204212' target=_blank style='color:#2F92EE;'>#样本量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62042, encryptionId=302e6204212, topicName=样本量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sun Sep 03 11:54:00 CST 2017, time=2017-09-03, status=1, ipAttribution=)]
    2018-04-30 xugc
  3. [GetPortalCommentsPageByObjectIdResponse(id=1984130, encodeId=024319841307e, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Dec 24 04:54:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756160, encodeId=d9d31e561605c, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Mon Apr 30 22:54:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669374, encodeId=3dca16693e499, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Jan 22 01:54:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775338, encodeId=0fce1e75338cd, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Oct 24 12:54:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283474, encodeId=737f12834e408, content=<a href='/topic/show?id=302e6204212' target=_blank style='color:#2F92EE;'>#样本量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62042, encryptionId=302e6204212, topicName=样本量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sun Sep 03 11:54:00 CST 2017, time=2017-09-03, status=1, ipAttribution=)]
    2018-01-22 zhzhxiang
  4. [GetPortalCommentsPageByObjectIdResponse(id=1984130, encodeId=024319841307e, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Dec 24 04:54:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756160, encodeId=d9d31e561605c, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Mon Apr 30 22:54:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669374, encodeId=3dca16693e499, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Jan 22 01:54:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775338, encodeId=0fce1e75338cd, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Oct 24 12:54:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283474, encodeId=737f12834e408, content=<a href='/topic/show?id=302e6204212' target=_blank style='color:#2F92EE;'>#样本量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62042, encryptionId=302e6204212, topicName=样本量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sun Sep 03 11:54:00 CST 2017, time=2017-09-03, status=1, ipAttribution=)]
    2017-10-24 amyloid
  5. [GetPortalCommentsPageByObjectIdResponse(id=1984130, encodeId=024319841307e, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Dec 24 04:54:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756160, encodeId=d9d31e561605c, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Mon Apr 30 22:54:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669374, encodeId=3dca16693e499, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Mon Jan 22 01:54:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775338, encodeId=0fce1e75338cd, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Oct 24 12:54:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283474, encodeId=737f12834e408, content=<a href='/topic/show?id=302e6204212' target=_blank style='color:#2F92EE;'>#样本量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62042, encryptionId=302e6204212, topicName=样本量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sun Sep 03 11:54:00 CST 2017, time=2017-09-03, status=1, ipAttribution=)]

相关资讯

Lancet子刊:机器学习为临床研究阴性结果“平反”(Look AHEAD研究)

2012年,著名的Look AHEAD(糖尿病健康行动)临床试验因为阴性结果而被提前终止,这个结果曾经令业内人士大跌眼镜。不过根据最近发表在 The Lancet Diabetes & Endocrinology(《柳叶刀糖尿病和内分泌学》)的研究成果,通过采用机器学习方法进行分析后,当年被提前终止的阴性结果Look AHEAD可以“平反”了。西奈山伊坎医学院全球卫生研究所的数据科学研究人

重大疾病临床研究组建“航母”,提升临床研究能力

围绕心血管疾病、恶性肿瘤、呼吸系统疾病等11个疾病领域建设起32个国家临床医学研究中心,依托30家相应疾病防控领域实力最强、水平最高的三甲医院,联合约260个地级市的2100余家的各级医疗机构,组建高水平临床研究平台和协同创新“航母编队”……自2012年以来,经过4年多的探索实践,我国重大疾病临床研究的“国家队”逐步形成。不仅在提升临床研究能力、加快临床转化方面取得实效,也在加速医药产品创新、系统

《药物非临床研究质量管理规范》(国家食品药品监督管理总局令第34号)

《药物非临床研究质量管理规范》(国家食品药品监督管理总局令第34号)

Eur Heart J:醒醒吧,别骗自己了。50万人随访12年的临床研究发现,健康的胖子可能并不存在

不过,在准备贴秋膘之前,我们应该好好看看伦敦帝国学院等36个研究机构联合做的一个史上最大的肥胖与心脏病的临床研究,这个大型的临床研究跨越12年,涉及欧洲10国的52万人。

Ann Intern Med:中医方剂随机对照试验报告国际标准(CONSORT CHM formula 2017)制定——共同提升中医方剂临床研究水平

2017年6月27日是一个值得纪念的日子。中医方剂随机对照试验报告国际标准当日通过美国《内科学年鉴》正式向全球发布,以简体中文、繁体中文、英文三种文字同期发表,并配发编者社论。该标准历时十年余,由中国、加拿大、英国学者组成的国际核心团队共同完成,包括香港浸会大学协理副校长、中医药学院临床部主任、我分会副会长卞兆祥教授,四川大学华西医院、我分会顾问李幼平教授、吴泰相副教授,北京中医药大学东直门医院、

J Clin Periodontol:不同抗生素方案治疗重度慢性牙周炎的1年随机试验

评估不同剂量的甲硝唑(MTZ)和MTZ +阿莫西林(AMX)治疗广泛性慢性牙周炎(GChP)的临床效果。